New Research Poster Presentation 4.35: Extended-Release Dexmethylphenidate 30 Mg Provides Optimum Control of ADHD Symptoms up to 12 Hours Post-Dose: A Randomized, Double-Blind, Crossover Study of Children with ADHD

Friday, October 30, 2009 9:00 AM

Rafael Muniz, M.D., Novartis Pharmaceutical Corporation, East Hanover, NJ

Linda Pestreich, M.A., Novartis Pharmaceutical Corporation, East Hanover, NJ

Kevin McCague, M.A., Novartis Pharmaceutical Corporation, East Hanover, NJ

Americo Padilla, M.D., Miami Research Associates, South Miami, FL

Matthew Brams, M.D., Bayou City Research, Houston, TX

Ann Childress, M.D., Center for Psychiatry and Behavioral Medicine, Las Vegas, NV

		56th Annual Meeting Tentative Program Schedule
		Please note that this schedule is subject to change. The Program Book distributed at the Annual Meeting will have final information on dates, times, and speakers for each presentation.

New Research Poster Presentation 4.35 Extended-Release Dexmethylphenidate 30 Mg Provides Optimum Control of ADHD Symptoms up to 12 Hours Post-Dose: A Randomized, Double-Blind, Crossover Study of Children with ADHD